<DOC>
	<DOCNO>NCT00290667</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisone , work different way stop growth cancer cell , either kill cell stop divide . Giving rituximab together combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together combination chemotherapy work treat old patient previously untreated B-cell lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Older Patients With Previously Untreated B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pharmacokinetic profile pharmacokinetics-based rituximab within CHOP-14 regimen comprise cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone elderly patient previously untreated aggressive B-cell lymphoma . - To determine whether increased single-doses rituximab male compensate low serum level . - Evaluate safety toxicity profile regimen male patient . Secondary - Determine rate complete response , primary progression therapy , event-free survival , progression-free survival , overall survival patient treat regimen . - Determine rate primary progression patient treat regimen . OUTLINE : This multicenter study . All patient undergo follow treatment . - Prephase treatment : Patients receive vincristine subcutaneously day -6 oral prednisone day -6 0 . - Immunochemotherapy radiotherapy : Patients receive CHOP chemotherapy comprise cyclophosphamide IV 15 minute , doxorubicin hydrochloride IV , vincristine IV day 1 oral prednisone daily day 1-5 . Patients also receive pegfilgrastim subcutaneously day 4 , 18 , 32 , 46 , 60 , 74 . Treatment CHOP chemotherapy repeat every 14 day 6 course absence disease progression unacceptable toxicity . Patients show response course 4 CHOP chemotherapy proceed salvage chemotherapy study . Patients evaluate 2-4 week completion CHOP . Patients initial bulky disease ( i.e. , diameter ≥ 7.5 cm ) extranodal involvement AND achieve complete remission ( CR ) , unconfirmed CR ( CRu ) , partial remission undergo radiotherapy 5 day week 4 week . Patients achieve CR CRu 2 month completion radiotherapy proceed salvage chemotherapy study . Patients stratify accord center , International Prognostic Index ( 1-2 v 3-5 ) , disease involvement ( bulky v extranodal v bulky and/or extranodal ) , age ( 61-70 year old vs 71-80 year old ) , gender . Patients randomize 1 2 treatment arm . - Arm I ( 2-weekly rituximab ) : Patients receive rituximab IV 375 mg/m^2 ( female ) 500 mg/m^2 ( male ) 4 hour day 0 , 14 , 28 , 42 , 56 , 70 , 84 , 98 . Patients also receive pegfilgrastim subcutaneously day 4 course . - Arm II ( pharmacokinetic-based dose-dense rituximab ) : Patients receive rituximab IV 375 mg/m^2 ( female ) 500 mg/m^2 ( male ) 4 hour day -1 , 0 , 3 , 7 , 14 , 21 , 28 , 42 . Patients also receive pegfilgrastim subcutaneously day 4 course . Some patient undergo blood sample collection periodically treatment pharmacokinetic study . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , year therafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histological diagnosis aggressive Bcell lymphoma Previously untreated disease Stage IIV disease CD20positive disease Any International Prognostic Index ( IPI ) score No secondary lymphoma prior chemotherapy radiotherapy No primary CNS lymphoma No primary gastrointestinal ( MALT ) lymphoma PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month AST ALT ≤ 3 time normal unless related lymphoma Bilirubin ≤ 2 mg/dL unless related lymphoma Creatinine ≤ 2 time normal unless related lymphoma Fertile patient must use effective contraception No known allergic reaction foreign proteins No active infection require systemically administer antibiotic antiviral medication No noncompensated heart failure No dilatative cardiomyopathy No coronary heart disease STsegment depression ECG No myocardial infarction past 6 month No chronic lung disease hypoxemia No severe noncompensated hypertension No severe noncompensated diabetes mellitus No clinical sign cerebral dysfunction No severe psychiatric disease No known HIV infection No active chronic hepatitis B C infection No concurrent diseases exclude administration therapy outline study protocol PRIOR CONCURRENT THERAPY : See Disease Characteristics More 12 week since prior clinical trial participation No prior participation study No prior therapy , include murine antibody , cancer No prior organ transplantation No concurrent responseadapted radiotherapy ( `` iceberg radiotherapy '' ) No concurrent anticancer chemotherapy study medication</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>